Profiling of 3696 nuclear receptor-coregulator interactions: A resource for biological and clinical discovery

Endocrinology

Volumn 159, Issue 6, 2018, Pages 2397-2406

  Broekema, Marjoleine F ^a   Hollman, Danielle A A ^a   Koppen, Arjen ^a   Van Den Ham, Henk Jan ^b   Melchers, Diana ^c   Pijnenburg, Dirk ^c   Ruijtenbeek, Rob ^c   Van Mil, Saskia W C ^a   Houtman, René ^c   Kalkhoven, Eric ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PamGene International BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARNESOID X RECEPTOR; GLUCOCORTICOID RECEPTOR; LIVER X RECEPTOR; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR; CELL RECEPTOR; COREPRESSOR PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; GENE EXPRESSION PROFILING; LIGAND BINDING; MOLECULAR PHYLOGENY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; ANIMAL; CLUSTER ANALYSIS; DRUG DESIGN; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; PHYLOGENY; PROCEDURES; PROTEIN ANALYSIS; PROTEIN DATABASE; STANDARDS; SUPPLY AND DISTRIBUTION;

ANIMALS; CLUSTER ANALYSIS; CO-REPRESSOR PROTEINS; DATABASES, PROTEIN; DRUG DESIGN; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHYLOGENY; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN INTERACTION MAPPING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 85054423283     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2018-00149     Document Type: Article

References (81)

1. Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157(1):255-266.
2. Achermann JC, Schwabe J, Fairall L, Chatterjee K. Genetic disorders of nuclear receptors. J Clin Invest. 2017;127(4):1181-1192.
3. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature. 2008;456(7220):350-356.
4. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F. Multidomain integration in the structure of the HNF-4a nuclear receptor complex. Nature. 2013;495(7441):394-398.
5. Lou X, Toresson G, Benod C, Suh JH, Philips KJ, Webb P, Gustafsson JA. Structure of the retinoid X receptor a-liver X receptor b (RXRa-LXRb) heterodimer on DNA. Nat Struct Mol Biol. 2014;21(3):277-281.
6. Chandra V, Wu D, Li S, Potluri N, Kim Y, Rastinejad F. The quaternary architecture of RARb-RXRa heterodimer facilitates domain-domain signal transmission. Nat Commun.2017;8(1):868.
7. Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. Understanding nuclear receptor form and function using structural biology. J Mol Endocrinol. 2013;51(3):T1-T21.
8. Nagy L, Schwabe JWR. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci. 2004;29(6):317-324.
9. Jeyakumar M, Tanen MR, Bagchi MK. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Mol Endocrinol. 1997; 11(6):755-767.
10. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 1999;18(7):1900-1904.
11. Tagami T, Madison LD, Nagaya T, Jameson JL. Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol. 1997;17(5):2642-2648.
12. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, Saatcioglu F. Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem. 2002;277(51):49517-49522.
13. Hu X, Lazar MA. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature. 1999; 402(6757):93-96.
14. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387(6634):733-736.
15. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, Mader S, Han VK, Yang XJ, White JH. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell. 2003;11(1):139-150.
16. Kojetin DJ, Matta-Camacho E, Hughes TS, Srinivasan S, Nwachukwu JC, Cavett V, Nowak J, Chalmers MJ, Marciano DP, Kamenecka TM, Shulman AI, Rance M, Griffin PR, Bruning JB, Nettles KW. Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. Nature Communications. 2015;6:8013.
17. Millard CJ, Watson PJ, Fairall L, Schwabe JWR. An evolving understanding of nuclear receptor coregulator proteins. J Mol Endocrinol. 2013;51(3):T23-T36.
18. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998;12(21):3357-3368.
19. Guan H-P, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Core-pressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 2005;19(4):453-461.
20. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295(5564):2465-2468.
21. Paruthiyil S, Cvoro A, Zhao X, Wu Z, Sui Y, Staub RE, Baggett S, Herber CB, Griffin C, Tagliaferri M, Harris HA, Cohen I, Bjeldanes LF, Speed TP, Schaufele F, Leitman DC. Drug and cell type-specific regulation of genes with different classes of estrogen receptor b-selective agonists. PLoS One. 2009;4(7):e6271.
22. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev. 2007;28(5):575-587.
23. Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 1998;17(1): 232-243.
24. Stafslien DK, Vedvik KL, De Rosier T, Ozers MS. Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Mol Cell Endocrinol. 2007;264(1-2):82-89.
25. Gowda K, Marks BD, Zielinski TK, Ozers MS. Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-g using time-resolved fluorescence resonance energy transfer. Anal Biochem. 2006;357(1):105-115.
26. Zhou G, Cummings R, Hermes J, Moller DE. Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation. Methods. 2001;25(1):54-61.
27. Folkertsma S, van Noort PI, de Heer A, Carati P, Brandt R, Visser A, Vriend G, de Vlieg J. The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor a ligand-binding domain. Mol Endocrinol. 2007;21(1):30-48.
28. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. Peptide antagonists of the human estrogen receptor. Science. 1999;285(5428): 744-746.
29. Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ. Selection of estrogen receptor b- and thyroid hormone receptor b-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol Endocrinol. 2000;14(5):605-622.
30. Paige LA, Christensen DJ, Grøn H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER a and ER b. Proc Natl Acad Sci USA. 1999;96(7):3999-4004.
31. Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM, McDonnell DP. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol Endocrinol. 2007;21(10): 2361-2377.
32. Iannone MA, Simmons CA, Kadwell SH, Svoboda DL, Vanderwall DE, Deng SJ, Consler TG, Shearin J, Gray JG, Pearce KH. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol Endocrinol. 2004;18(5):1064-1081.
33. Goodson ML, Farboud B, Privalsky ML. An improved high throughput protein-protein interaction assay for nuclear hormone receptors. Nucl Recept Signal. 2007;5:e002.
34. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, Kern R, Koegl M. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics. 2005;4(2): 205-213.
35. Kim SH, Tamrazi A, Carlson KE, Katzenellenbogen JA. A pro-teomic microarray approach for exploring ligand-initiated nuclear hormone receptor pharmacology, receptor selectivity, and heterodimer functionality. Mol Cell Proteomics. 2005;4(3):267-277.
36. Albert S, Gaudan S, Knigge H, Raetsch A, Delgado A, Huhse B, Kirsch H, Albers M, Rebholz-Schuhmann D, Koegl M. Computer-assisted generation of a protein-interaction database for nuclear receptors. Mol Endocrinol. 2003;17(8):1555-1567.
37. Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E. Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor g cofactor. Mol Cell Proteomics. 2009;8(10):2212-2226.
38. Wang S, Houtman R, Melchers D, Aarts J, Peijnenburg A, van Beuningen R, Rietjens I, Bovee TF. A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds. ALTEX. 2013;30(2): 145-157.
39. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948.
40. Boc A, Diallo AB, Makarenkov V. T-REX: a web server for inferring, validating and visualizing phylogenetic trees and networks. Nucleic Acids Res. 2012;40(Web Server issue, W1)W573-W579.
41. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem. 1999;274(25):17599-17604.
42. van Beekum O, Brenkman AB, Grøntved L, Hamers N, van den Broek NJ, Berger R, Mandrup S, Kalkhoven E. The adipogenic acetyltransferase Tip60 targets activation function 1 of peroxisome proliferator-activated receptor g. Endocrinology. 2008;149(4): 1840-1849.
43. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377(6548):454-457.
44. Yuan C-X, Ito M, Fondell JD, Fu Z-Y, Roeder RG. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci USA. 1998;95(14):7939-7944.
45. Oñate SA, Tsai SY, Tsai M-J, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270(5240):1354-1357.
46. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Burris TP, Griffin PR. The benzene-sulfoamide T0901317 (2,2,2-Trifluoroethyl)[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-a/g inverse A. Mol Pharmacol. 2010;77(2):228-236.
47. Busch BB, Stevens WC Jr, Martin R, Ordentlich P, Zhou S, Sapp DW, Horlick RA, Mohan R. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor a. J Med Chem. 2004;47(23):5593-5596.
48. Coward P, Lee D, Hull MV, Lehmann JM. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor g. Proc Natl Acad Sci U S A. 2001;98(15):8880-8884.
49. Tremblay GB, Bergeron D, Giguere V. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors b and g. Endocrinology. 2001;142(10): 4572-4575.
50. Kersten S, Kelleher D, Chambon P, Gronemeyer H, Noy N. Ret-inoid X receptor alpha forms tetramers in solution. Proc Natl Acad Sci U S A. 1995;92(19):8645-8649.
51. Gampe RT Jr, Montana VG, Lambert MH, Wisely GB, Milburn MV, Xu HE. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev. 2000;14(17):2229-2241.
52. Kersten S, Pan L, Chambon P, Gronemeyer H, Noy N. Role of ligand in retinoid signaling: 9-cis-retinoic acid modulates the oligomeric state of the retinoid X receptor. Biochemistry. 1995; 34(42):13717-13721.
53. Chang C, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors a and b. Mol Cell Biol. 1999;19(12):8226-8239.
54. Clarisse D, Thommis J, Van Wesemael K, Houtman R, Ratman D, Tavernier J, Offner F, Beck I, De Bosscher K. Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies. Onco-target. 2017;8(65):109675-109691.
55. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP, Pandolfi PP. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet. 1999;23(3): 287-295.
56. Gaughan L, Brady ME, Cook S, Neal DE, Robson CN. Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem. 2001;276(50):46841-46848.
57. Gelman L, Zhou G, Fajas L, Raspé E, Fruchart J-C, Auwerx J. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem. 1999;274(12):7681-7688.
58. Desmet SJ, Dejager L, Clarisse D, Thommis J, Melchers D, Bastiaensen N, Ruijtenbeek R, Beck IM, Libert C, Houtman R, Meijer OC, De Bosscher K. Cofactor profiling of the glucocorticoid receptor from a cellular environment. Methods Mol Biol. 2014;1204:83-94.
59. Picard F, Géhin M, Annicotte J, Rocchi S, Champy MF, O'Malley BW, Chambon P, Auwerx J. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell. 2002; 111(7):931-941.
60. Ye X, Han SJ, Tsai SY, DeMayo FJ, Xu J, Tsai MJ, O'Malley BW. Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci U S A. 2005;102(27):9487-9492.
61. Aarts JMMJG, Wang S, Houtman R, van Beuningen RM, Westerink WM, Van De Waart BJ, Rietjens IM, Bovee TF. Robust array-based coregulator binding assay predicting ERa-agonist potency and generating binding profiles reflecting ligand structure. Chem Res Toxicol. 2013;26(3):336-346.
62. Prekovic S, van Royen ME, Voet ARD, Geverts B, Houtman R, Melchers D, Zhang KY, Van den Broeck T, Smeets E, Spans L, Houtsmuller AB, Joniau S, Claessens F, Helsen C. The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther. 2016;15(7):1702-1712.
63. Houtman R, de Leeuw R, Rondaij M, et al. Serine-305 phos-phorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol Cancer Ther. 2012;11(4):805-816.
64. Métivier R, Penot G, Flouriot G, Pakdel F. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 a-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol. 2001;15(11):1953-1970.
65. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol. 1998;12(8): 1172-1183.
66. Devarakonda S, Gupta K, Chalmers MJ, Hunt JF, Griffin PR, Van Duyne GD, Spiegelman BM. Disorder-to-order transition underlies the structural basis for the assembly of a transcriptionally active PGC-1a/ERRg complex. Proc Natl Acad Sci USA. 2011;108(46): 18678-18683.
67. Takacs M, Petoukhov MV, Atkinson RA, Roblin P, Ogi FX, Demeler B, Potier N, Chebaro Y, Dejaegere A, Svergun DI, Moras D, Billas IM. The asymmetric binding of PGC-1a to the ERRa and ERRg nuclear receptor homodimers involves a similar recognition mechanism. PLoS ONE. 2013;8(7):e67810. doi:.
68. Lam V, Zheng J, Griffin PR. Unique interactome network signatures for PPARgamma modulation by functional selective ligands. Mol Cell Proteomics. 2017;16(12):2098-2110.
69. Foulds CE, Feng Q, Ding C, Bailey S, Hunsaker TL, Malovannaya A, Hamilton RA, Gates LA, Zhang Z, Li C, Chan D, Bajaj A, Callaway CG, Edwards DP, Lonard DM, Tsai SY, Tsai MJ, Qin J, O'Malley BW. Proteomic analysis of coregulators bound to ERa on DNA and nucleosomes reveals coregulator dynamics. Mol Cell. 2013;51(2):185-199.
70. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 1995;377(6548): 451-454.
71. Becares N, Gage MC, Pineda-Torra I. Posttranslational modifications of lipid-activated nuclear receptors: focus on metabolism. Endocrinology. 2017;158(2):213-225.
72. de Vera IMS, Zheng J, Novick S, Shang J, Hughes TS, Brust R, Munoz-Tello P, Gardner WJ Jr, Marciano DP, Kong X, Griffin PR, Kojetin DJ. Synergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA. Structure. 2017;25(10): 1506-1518.e4.
73. Lonard DM, O'malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 2007; 27(5):691-700.
74. Liu XF, Bagchi MK. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem. 2004;279(15): 15050-15058.
75. Murakami S, Nagari A, Kraus WL. Dynamic assembly and activation of estrogen receptor a enhancers through coregulator switching. Genes Dev. 2017;31(15):1535-1548.
76. Hager GL, Nagaich AK, Johnson TA, Walker DA, John S. Dynamics of nuclear receptor movement and transcription. Biochim BiophysActa. 2004;1677(1):46-51.
77. Miranda TB, Morris SA, Hager GL. Complex genomic interactions in the dynamic regulation of transcription by the glucocorticoid receptor. Mol Cell Endocrinol. 2013;380(1-2):16-24.
78. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19-34.
79. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARg signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557-566.
80. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-465.
81. Hollman DAA, Milona A, van Erpecum KJ, van Mil SWC. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 2012;1821(11): 1443-1452.